While vitamin A (VA) has been implicated in host resistance to infectious disease, little is known about the role of VA and its active metabolite, retinoic acid (RA) in host defenses against cancer. Here we show that local RA production within the tumor microenvironment (TME) is increased up to 5-fold compared to naïve surrounding tissue, with a commensurate increase in RA signaling to regionally infiltrating tumor-reactive T cells. Conditional disruption of RA signaling in CD8
Ͷ

Introduction
The morphogenic role of the active form of Vitamin A, retinoic acid (RA) in controlling spatial and temporal developmental patterning has underscored the powerful and essential function of this mediator during embryogenesis (1, 2) .
Similarly, within the immune system, RA has been shown to exert profound effects as a differentiation factor in inducing gut homing of leukocytes (3) (4) (5) (6) , the differentiation and stability of adaptive regulatory T cells (7) (8) (9) , the differentiation of CD4 + T cells toward Th1/Th17 cells (10, 11) , IgA class switching in B cells (6) and the differentiation of myeloid cells (12, 13) . It has been proposed that regionalized production of RA is critical for its role as an immune differentiation factor (11). Genetic approaches of ablating RA signaling in T cells have established how RA influences CD4 + T cell response in vivo (10, 11) , but little is known concerning its role in governing CD8 + T cell responsiveness. Given the well-recognized role of RA in supporting T cell responses, and the need for robust T cell responses in the development of protective anti-tumor immunity (14) , the role of RA in the host resistance against cancer was addressed with a focus on CD8 + T cell expansion and function. The studies presented herein show that RA is abundantly produced within the TME and accumulates to levels much higher than in surrounding tissue. Selective disruption of RA signaling in CD8 + T cells incapacitates their ability to undergo effective clonal expansion in vivo and as such, interferes with the development of protective anti-tumor immunity. ATRA measurement Tumor, tumor-draining lymph node (TDLN) and spleen were taken from day 6 B16.OVA-bearing or naïve mice. Liquid chromatographytandem mass spectrometry was used as described previously to measure ATRA concentration (17) .
Materials and Methods
RALDH Activity Analysis RALDH activity in individual cells was estimated using ALDEFLUOR staining kits (StemCell Technologies, Vancouver, British Columbia, Canada), according to the manufacturer's protocol as previously described (18) . weeks later by staining with α-CD45.1 and α-CD45.2. All BMCs exceeded 96% reconstitution efficiency.
Immunization dnRARα and dnRARαCD4
Cre mice were immunized with 500μg
OValbumin (Sigma-Aldrich), 50μg αCD40 (BioXcell) and 50μg polyI:C (InvivoGen) by i.p. injection.
Analysis of MHC-I Tetramer and IFNγ by flow cytometery
MHCI-I Tetramer and IFNγ staining was performed as previously described (19).
Four-color FACS ® data was collected on a BD FACSCalibur flow cytometer and analyzed using FlowJo software. Analysis typically pre-gated on CD8 + MHCII í cells.
ELISPOT Assay ELISPOT was done according to procedures described previously (20) . Briefly, CD8 + effector T cells were harvested from spleen, TDLN, or TILs of day 12 B16.OVA-bearing mice, and plated at 1:1 ratio with irradiated T cell-depleted C57BL/6 splenocytes pulsed with 10ȝg/ml SIINFEKL peptide (or without peptide as control). Plates were incubated for 20h at 37°C and then developed with aminoethylcarbazole chromogen.
Phenotype Analysis of OVA-Specific CD8 + T Cells Enrichment was done at different time-points as described previously (21) and stained as described in the text. 
Statistical Analysis
Results
Heightened RA signaling and RA synthesis within the TME We previously reported that inflammatory mediators induced a spatially-and temporally-restricted induction of RA synthesis and signaling in vivo (11). To determine if tumor growth in vivo induced restricted and heightened RA signaling and synthesis, a tumor that reports RA signaling was injected in vivo. During the growth of B16.OVA-DR5-Luciferase, in which the RA response element, DR5
repeat, is coupled to a luciferase reporter, an increase of RA signaling over the tumor growth course (Fig 1A) was observed. The reporting signal was RAdependent as it was inhibited by the administration of pan-RAR antagonist (NRX 194310) (data not shown). The same RA reporting signal was also observed using B16-DR5-Luciferase cells, indicating that expression of OVA was not critical for induction of RA (data not shown). To confirm that enhanced RA synthesis at the tumor site was induced during tumor growth, DR5-Luciferase transgenic reporter mice were employed which express DR5-luciferase in all tissues (4). B16.OVA tumor cells were injected into DR5-Luciferase mice and RA signaling could be readily detected primarily at the growing tumor site by day 6 (Fig 1B) . The induced RA signaling was also observed in other tumor models, like EL4 thymoma, MB49 urothelial cacrcinoma and B16 melanoma (data not shown). To distinguish RA signaling in hematopoietic cells and/or non- ͻ hematopoietic compartment in the TME, bone marrow chimeras (BMC) were generated (designated as donor BMĺlethally irradiated recipient): DR5-Luciferase→C57BL/6 and C57BL/6→DR5-Luciferase. Local RA responses in the TME were observed in both recipients as non-reconstituted mice, indicating RA signaling in both hematopoietic and non-hematopoietic cells (Fig 1C) .
To directly measure RA synthesis within the TME, ATRA concentrations from TDLN, spleen and tumor site were quantified by liquid chromatography-tandem mass spectrometry. Data showed that ATRA was significantly increased (~5 fold) in tumor tissue compared to naïve skin (Fig 1D) . The same trend was also true when ATRA quantity in TDLN was compared to that in naïve LN (~2 fold increase). Conversely, no significant difference was observed in the ATRA levels between spleen from naïve mice and B16.OVA-bearing mice. Taken together, these results showed that RA synthesis and signaling is elicited locally in response to tumor growth in vivo.
The host but not the tumor produces RA to enhance RA concentration in the TME A series of studies were designed to determine the relative contribution of the host and tumor cells to elevated levels of RA in the TME. Attention was turned to identifying host cells producing elevated levels of ATRA within the TME. RA is constitutively produced in naïve skin ( Fig 2D, ͳͳ the data suggests that the tumor-infiltrating DCs and macrophages contribute to RA-enriched TME.
RA signaling occurs in CD8 + T cells within the TME and TDLN
Further studies were designed to determine the lineage of cells being signaled by RA within the TME and TDLN. To identify the hematopoietic cells reporting RA signaling, specific cell lineages were purified from tumor-infiltrating lymphocytes Fig S1A) . In addition, it was confirmed that CD8 + T cells in dnRARαCD4
Cre were unresponsive to RA in vitro, as shown by the inability to upregulate α4β7 in response to RA (Supplemental Fig S1B) (Fig 4D) suggesting reduced immune surveillance. The enhanced tumor growth is independent of deficient CD4 + T cell help because the same effect was observed when CD4 + T cells were depleted in both groups over the entire tumor growth course (Fig 4E) . Chemical inhibition of RA signaling recapitulated the phenotype observed in the dnRARαCD4 Cre mice (Fig 4F) . In vitro culture experiments established that the pan-RAR antagonist used in this 
ͳͶ study did not inhibit B16.OVA growth over a wide dose range (data not shown).
In conclusion, these studies establish that RA signaling to CD8 + T cells in vivo is critical for optimal suppression of tumor growth.
RA signaling is required for CD8 + T cell expansion in vivo
To gain greater insights into the underlying mechanism of RA controlling CD8 + T cell clonal expansion, a more robust CD8 + T cell response induced by CD40
agonist, together with a TLR agonist and soluble antigen system was exploited (19). As observed in the B16.OVA tumor model, dnRARαCD4 Cre mice showed a significant decrease in the frequency of OVA-specific CD8 + T cells compared to control dnRARα mice (14.9% vs. 0.6%; Fig 5A and 5B). CD44 hi OVA-tetramer + CD8 + T cells were quantified in the blood, spleen, mesenteric LN (MLN), and peripheral LN (PLN) on peak response time of day 6 to ensure that the reduced frequency in the blood was not due to a trafficking defect but rather was representative of the overall CD8 + T cell response (Fig 5C) . When re-stimulated ex vivo by SIINFEKL peptide or αCD3, the frequency of IFNγ-producing CD8 + T cells in dnRARαCD4 Cre was significantly lower than in dnRARα mice (Fig 5D and   5E ). Identical results were obtained in mice that were depleted of CD4 + T cells (Supplemental Fig S2) , establishing that intrinsic RA signaling deficiency in CD8 + but not CD4 + T cells accounted for the defective CD8 + T cell accumulation.
RA is responsible for the late clonal expansion of CD8 + T cells
Tetramer enrichment allowed for the quantification of total OVA-tetramer + CD8 + T cells at very early time points following immunization (21). On day 1 and 4 post- (Fig 6A-B) , indicating that the expression of dnRARα imparts no effect on early T cell activation. During the initial expansion between day 0 and 4, OVA-tetramer + CD8 + T cells in dnRARαCD4 Cre mice accumulated to the same extent as their counterparts in dnRARα mice, demonstrated by the same ~4-fold increase over naïve control (Fig 6C) . However, OVA-specific CD8 + T cells failed to accumulate further between day 4 and 6 in dnRARαCD4 Cre mice while the counterparts in dnRARα mice expanded logarithmically (~50-fold).
Analysis of proliferation of OVA-specific CD8 + T cells by BrdU incorporation
between day 4 and 6, revealed a slight but not significant decrease in OVAtetramer + cells incorporating BrdU between dnRARα and dnRARαCD4 Cre (both between 40-50%) (Fig 6D-E (Fig 6D) . Therefore, the abortive accumulation of OVA-specific CD8 + T cells in dnRARαCD4 Cre mice between day 4 and 6 post-immunization may be due to an equal number of cells undergoing proliferation and apoptosis simultaneously (Fig 6E) . In conclusion, although early 
ʹʹ naïve mice were collected on day 6 and ATRA concentration was measured.
Each value represents the same tissue pooled from 4 mice. Shown data is pooled from 2 experiments. In all experiments shown here, statistically significant differences were determined by t test. ʹ͵ mice/group) and data shown in E is pooled from 2 experiments (n=6-7 mice/group). Statistically significant differences were determined by t test. 
